Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and 2nd-gen ADT in African Americans with mCRPC
NCT03770455Phase 2Terminated
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in metastatic castration-resistant prostate cancer (mCRPC). Primary endpoint: Prostate-Specific Antigen Response Greater Than or Equal to 50% at 6 months. Started Jan 2019; status: terminated.
02
Drugs
avelumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03770455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770455.